To install click the Add extension button. That's it.
The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.
How to transfigure the Wikipedia
Would you like Wikipedia to always look as professional and up-to-date? We have created a browser extension. It will enhance any encyclopedic page you visit with the magic of the WIKI 2 technology.
Try it — you can delete it anytime.
Install in 5 seconds
Yep, but later
4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals.[4] It was approved for the treatment of major depressive disorder in the United States in September 2023.[4] This came after the drug had been rejected by the Food and Drug Administration three times over two decades due to insufficient evidence of effectiveness.[5]
YouTube Encyclopedic
1/5
Views:
735
475
1 535
25 016
1 010 721
Exxua (gepirone): the newly approved antidepressant
FDA approval of gepirone - EXXUA
Gepirone (Exxua): New Antidepressant FDA Approved for MDD
BUSPAR | 5 Must Know Facts!
What To Avoid When Taking Sertraline, Fluoxetine, Paroxetine, Escitalopram (SSRIs)
Transcription
Medical uses
Gepirone is indicated for the treatment of major depressive disorder in adults.[1] Of 15 clinical trials of gepirone for major depressive disorder submitted to the United States Food and Drug Administration (FDA), three were excluded for methodological reasons, three were deemed "failed" and "uninformative", seven were deemed negative and did not demonstrate effectiveness, and two were deemed positive and did show effectiveness.[6] Two positive trials are needed for FDA drug approval, with this being the case regardless of the number of negative trials.[7] In the two positive trials of gepirone for depression, the drug significantly outperformed placebo in terms of depressive symptom reduction and showed effect sizes similar to those of other approved antidepressants.[1][8] In both trials, gepirone reduced depressive symptoms by about 2.5 points more than placebo on the 52-point Hamilton Depression Rating Scale (17-item version or HAMD-17).[1] The baseline depression scores in the trials ranged from 22.7 to 24.2 in the different patient groups.[1]
It is not known if gepirone is safe in women who are breastfeeding. Medications with more data in this setting may be preferred.[9]
Contraindications
Gepirone is contraindicated in people that have experienced an allergic reaction to gepirone, a corrected QT interval > 450 msec, a history of congenital long QT syndrome, use medications that strongly inhibit CYP3A4 (an enzyme involved in gepirone's metabolism), severe liver problems, or have used a monoamine oxidase inhibitor medication within 14 days.[1]
Side effects
Serious side effects of gepirone include QT prolongation (increases the risk of a potentially life-threatening cardiac arrhythmia called torsade de pointes), serotonin syndrome (especially in the presence of other serotonergic drugs), and activation of mania or hypomania in people with bipolar disorder. Common side effects include dizziness, nausea, insomnia, abdominal pain, and dyspepsia (indigestion).[1]
The absolute bioavailability of gepirone is 14 to 17%.[1] The time to peak concentrations of gepirone with the extended-release formulation is 6hours.[1] When taken with a high-fat meal, the time to peak levels decreases to 3hours.[1] A high-fat meal increases exposure to gepirone, with the effect increasing dependent on the amount of fat in the meal.[1]Peak concentrations were increased by 27% with a low-fat meal, 55% with a medium-fat meal, and 62% with a high-fat meal, while area-under-the-curve levels of gepirone were increased by 14% with a low-fat meal, 22% with a medium-fat meal, and 32 to 37% with a high-fat meal.[1] The effect was similar for the metabolites of gepirone, 1-PP and 3'-hydroxygepirone (3'-OH-gepirone).[1]
Distribution
The apparent volume of distribution of gepirone is approximately 94.5L.[1] The plasma protein binding of gepirone in vitro is 72% and is independent of concentration.[1] The plasma protein binding of 3'-OH-gepirone is 59% and of 1-PP is 42%.[1]
Metabolism
Gepirone is metabolized primarily by CYP3A4.[1] Its major metabolites are 1-PP and 3'-OH-gepirone, both of which are pharmacologically active.[1] These metabolites are present in the circulation at higher concentrations than gepirone.[1]
Elimination
With a single oral dose of radiolabeled gepirone, 81% is recovered in urine and 13% is recovered in feces as metabolites.[1] About 60% of the gepirone is eliminated in urine within 24hours.[1]
The terminal half-life of gepirone as the extended-release form is approximately 5hours.[1]
Gepirone was developed by Bristol-Myers Squibb in 1986,[5] but was out-licensed to Fabre-Kramer in 1993. The FDA rejected approval for gepirone in 2002 and 2004.[5] It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2009. However, in 2012 it once again failed to convince the FDA of its qualities for treating anxiety and depression.[5] In December 2015, the FDA once again gave gepirone a negative review for depression due to concerns of efficacy.[12] However, in March 2016, the FDA reversed its decision and gave gepirone ER a positive review.[13] Gepirone ER was finally approved for the treatment of major depressive disorder in the United States in September 2023.[5]
Society and culture
Names
The brand name of gepirone is Exxua.[1] Former tentative brand names which were never used included Ariza, Variza, and Travivo.[4]
^ abFabre LF, Brown CS, Smith LC, Derogatis LR (May 2011). "Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women". The Journal of Sexual Medicine. 8 (5): 1411–1419. doi:10.1111/j.1743-6109.2011.02216.x. PMID21324094.
^ abFabre LF, Clayton AH, Smith LC, Goldstein I, Derogatis LR (March 2012). "The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men". The Journal of Sexual Medicine. 9 (3): 821–829. doi:10.1111/j.1743-6109.2011.02624.x. PMID22240272.